Analysts Issue Forecasts for Mesoblast FY2025 Earnings

Mesoblast Limited (NASDAQ:MESO) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Mesoblast in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will post earnings per share of ($0.70) for the year. The consensus estimate for Mesoblast’s current full-year earnings is ($0.74) per share.

A number of other brokerages also recently issued reports on MESO. Piper Sandler increased their price target on shares of Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a report on Thursday, December 19th. Jefferies Financial Group downgraded Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.50.

Mesoblast Stock Performance

Shares of NASDAQ MESO opened at $17.58 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The firm’s 50 day simple moving average is $14.51 and its 200-day simple moving average is $10.06. Mesoblast has a 12 month low of $1.72 and a 12 month high of $22.00.

Institutional Trading of Mesoblast

Several institutional investors have recently made changes to their positions in the company. Jane Street Group LLC grew its holdings in shares of Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after purchasing an additional 26,959 shares during the period. Marshall Wace LLP acquired a new position in Mesoblast in the second quarter valued at about $562,000. Lazari Capital Management Inc. boosted its stake in Mesoblast by 6.6% during the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock worth $364,000 after buying an additional 3,300 shares during the period. XY Capital Ltd acquired a new stake in shares of Mesoblast during the third quarter valued at about $244,000. Finally, Creative Planning purchased a new stake in shares of Mesoblast in the 3rd quarter valued at approximately $147,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.